J&J to build $2b facility in North Carolina to make future products
HQ Team October 2, 2024: Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating.
Drugs
Health
Pharma
Drugs
Health
Pharma
AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.
Drugs
Health
Pharma
Kezar Life Sciences halts mid-stage lupus nephritis trial after four people die
Kezar Life Sciences Inc., a US-based biotechnology company, has stopped a trial in patients with a type of kidney disease after four people.
Drugs
Health
Pharma
Roche arm to buy breast cancer portfolio from Regor for $850 million
Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.
Drugs
Health
Pharma
FDA faces Vanda’s ire as it rejects firm’s gastroparesis drug application
Vanda Pharmaceuticals Inc’s gastroparesis drug to treat a serious stomach condition was rejected by the Food and Drug Administration (FDA), which asked for.
Drugs
Health
Pharma
AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Climate
Health
Pharma
Global goal to cut methane emissions as distant as a ‘desert oasis’
A global goal to reduce methane emissions “ seems as distant as a desert oasis” now, as about two-thirds of it comes from.
Drugs
Health
Pharma
First batch of Bavarian Nordic’s mpox vaccines in Congo by Sept. 5
The World Health Organization expects the first delivery of mpox vaccines, made by Bavarian Nordic and donated by the European Union, today in.
Drugs
Health
Pharma
Abbott starts trial on deep brain stimulation for depressive disorder
Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a.
Drugs
Health
Pharma
Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.